All Agencies
1
1
Stories Covered
1
Total Articles
Articles & Crawled Pages
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.